Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 14/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393989 | 0.91 | TRPV1 (0.51) | CSNK1ECSNK1DTRPV1HTR2AHTR2C | |
| SCHEMBL14393986 | 0.89 | CSNK1E (0.52) | KITCSNK1ECSNK1DGPR142TRPV1 | |
| SCHEMBL13964287 | 0.85 | CSNK1E (0.52) | CSNK1ECSNK1D | |
| SCHEMBL13963925 | 0.85 | CSNK1E (0.53) | CSNK1ECSNK1DTRPV1HTR2AHTR2C | |
| SCHEMBL13964142 | 0.84 | CSNK1E (0.47) | CSNK1ECSNK1D | |
| SCHEMBL14394075 | 0.82 | CSNK1E (0.47) | CSNK1ECSNK1DTRPV1 | |
| SCHEMBL14393888 | 0.81 | CSNK1E (0.58) | CSNK1ECSNK1D | |
| SCHEMBL13964147 | 0.81 | CSNK1E (0.51) | CSNK1ECSNK1D | |
| SCHEMBL14368468 | 0.80 | CSNK1E (0.51) | CSNK1ECSNK1D | |
| SCHEMBL14368462 | 0.80 | CSNK1E (0.52) | CSNK1ECSNK1DGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | KIT 1838/4885CSNK1E 136/4885CSNK1D 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.